SCHEMBL1406706

SCHEMBL1406706

CC(C)CN(C)c1c(-c2ccc(C(C)(C)C)cc2)cc(C(=O)/C=C/c2ccc(C(=O)O)cc2)cc1C(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
TP53 P04637 2/20 0.53
MAPT P10636 2/20 0.53
CYP3A4 P08684 1/20 0.53
ALOX15 P16050 1/20 0.53
MAPK1 P28482 1/20 0.53
BLM P54132 1/20 0.53
CASP7 P55210 1/20 0.53
HSD17B10 Q99714 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
TNFRSF1A P19438 3/20 0.43
HPGD P15428 3/20 0.40
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
XDH P47989 1/20 0.37
STAT3 P40763 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1406717 1.00 SMN1; SMN2 (0.53) SMN1; SMN2TP53MAPTCYP3A4ALOX15
SCHEMBL1406846 0.93 MAPT (0.47) SMN1; SMN2TP53MAPTCYP3A4ALOX15
SCHEMBL1406848 0.93 MAPT (0.47) SMN1; SMN2TP53MAPTCYP3A4ALOX15
SCHEMBL1406671 0.88 SMN1; SMN2 (0.59) SMN1; SMN2TP53MAPTCYP3A4ALOX15
SCHEMBL1406810 0.88 SMN1; SMN2 (0.59) SMN1; SMN2TP53MAPTCYP3A4ALOX15
SCHEMBL1406464 0.86 MAPT (0.52) SMN1; SMN2TP53MAPTCYP3A4ALOX15
SCHEMBL6476863 0.82 SMN1; SMN2 (0.51) SMN1; SMN2TP53MAPTCYP3A4ALOX15
SCHEMBL1406634 0.81 SMN1; SMN2 (0.53) SMN1; SMN2TP53MAPTCYP3A4ALOX15
SCHEMBL1406635 0.81 SMN1; SMN2 (0.53) SMN1; SMN2TP53MAPTCYP3A4ALOX15
SCHEMBL1406685 0.79 TP53 (0.45) SMN1; SMN2TP53MAPTCYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP claimed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US claimed
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP disclosed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 US disclosed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG SMN1; SMN2 4756/4885TP53 427/4885MAPT 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.